Testimony Submitted to the Office of Human Research Protection (OHRP) by Vera Hassner Sharav and Marie M. Cassidy, Ph.D, D.Sc. April, 2001 AHRP recognizes that to include children in clinical trials for any medication presents a dilemma of truly Solomonic proportions. It is a choice between continuing the practice of…
Psychopharmacology in Turmoil: David Healy, MD Presentation Columbia + Debate Dr. Joseph Coyne, Ph.D Fri, 9 Dec 2005 Recent reports describing a determined effort to pathologize US infants and toddlers who are being declared to suffer from “severe mental disorders”–the latest, most aggressively marketed diagnosis for children is Bipolar disorder,…
Lilly Consultants dismiss significance of suicide risk while Lilly will issue Black Box warning label for Strattera Mon, 10 Oct 2005 On September 29, the FDA issued the public health advisory alerting health care professionals that children and adolescents taking Strattera prescribed for ADHD should be closely monitored for changes…
Forbes: Face of The Year: David Graham Mon, 13 Dec 2004 Forbes magazine has named Dr. David Graham the Face of the Year’ for his “steadfast advocacy of drug safety and his willingness to blow the whistle on his bosses.” Dr. Graham took a courageous stand as a responsible…
Go Slow on Mental Health Screening: Dr. Karen Effrem responds to New Freedom Commission Chair, Michael Hogan – Wash Times Sun, 31 Oct 2004 A letter to the editor in the Washington Times – Go slow on Mental Health Screening – by AHRP’s newest board member, pediatrician Dr. Karen Effrem,…
Public Comments Re: Smallpox Vaccine Trial on 2 to 5 Year Old Children Personally, I think it’s a bad idea to test the smallpox vaccine on children. Especially because of side effects. I can’t imagine anyone I know who has a child between theses agea allowing their child to be…
Follow the Money / Can the Institute of Medicine Review the FDA? Wed, 6 Apr 2005 A letter to the editor published in Nature Medicine by Dr. Bernard Carroll, a past chairman of the FDA Advisory Committee for Psychotropic Drugs, and past chairman of the Department of Psychiatry at Duke…
AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re: Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….
APA Claims Credit for Censoring News Report about Mental Screening Sun, 16 Oct 2005 The American Psychiatric Association acknowledges its role in suppressing a major news story about the President’s New Freedom Commission Report recommendation. That recommendation is the center of a heated debate among advocates for personal privacy, parental…
British Medical Journal: Something is rotten at the heart of FDA / Glaxo faces class action suit Sun, 5 Dec 2004 “Something is rotten at the heart of the FDA.” That’s the opening of an editorial in the British Medical Journal. [1] Indeed, there is something rotten at the heart…
Screening for Mental Illness–A Diabolical, Profit-Enhancing Experiment Fri, 22 Oct 2004 Concerned citizen groups are joining our effort to stop the government from implementing a sweeping recommendation for lifetime screening for mental illness. If implemented, the first to be screened for hidden mental illness are America’s 52 million school children…
Bayer/ Baycol on Trial in Texas_NYT Sat, 1 Mar 2003 Melody Peterson of the New York Times reports that in the first case brought against Bayer involving its anticholesterol drug, Baycol, a senior official of Bayer AG testified in court in Corpus Cristi, Texas. He acknowledged that company officials in…
